Claims for Patent: 10,238,643

Summary for Patent: 10,238,643

Title:	Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
Abstract:	Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
Inventor(s):	Eric Elenko, Philip E. Murray, III, Andrew C. Miller
Assignee:	Puretech Health LLC , Puretech Management Inc
Application Number:	US15/400,108
Patent Claims:	1. An oral medicament comprising: (a) between 25 mg and 700 mg xanomeline and/or a salt thereof used during a 24-hour period; (b) between 5 mg and 200 mg trospium chloride used during a 24-hour period; and (c) a pharmaceutically acceptable carrier; wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline. 2. The oral medicament of claim 1, formulated as an immediate release formulation. 3. The oral medicament of claim 1, formulated as a controlled release formulation. 4. The oral medicament of claim 1, wherein the xanomeline is formulated as a controlled release formulation and the trospium chloride is formulated as an immediate release formulation. 5. The oral medicament of claim 1, comprising between 25 mg and 225 mg xanomeline and between 5 mg and 60 mg trospium chloride in a single dosage form used during the 24-hour period. 6. The oral medicament of claim 5, comprising 25 milligrams xanomeline. 7. The oral medicament of claim 5, comprising 75 milligrams xanomeline. 8. The oral medicament of claim 5, comprising 6.5 milligrams trospium chloride. 9. The oral medicament of claim 5, comprising 20 milligrams trospium chloride. 10. The oral medicament of claim 5, in the form of a single capsule formulation consisting essentially of 25 milligrams xanomeline, 5 milligrams trospium chloride, and a pharmaceutically acceptable carrier. 11. The oral medicament of claim 5, in the form of a single capsule formulation consisting essentially of 75 milligrams xanomeline, 20 milligrams trospium chloride, and a pharmaceutically acceptable carrier. 12. The oral medicament of claim 5, in the form of a single capsule formulation consisting essentially of 25 milligrams xanomeline, 20 milligrams trospium chloride, and a pharmaceutically acceptable carrier. 13. The oral medicament of claim 5, in the form of a single capsule formulation consisting essentially of 75 milligrams xanomeline, 5 milligrams trospium chloride, and a pharmaceutically acceptable carrier. 14. The oral medicament of claim 1, wherein the pharmaceutically acceptable carrier comprises cellulose and lactose. 15. The oral medicament of claim 1, comprising between 25 mg and 300 mg xanomeline and between 5 mg and 200 mg trospium chloride in a single dosage form used during the 24-hour period. 16. The oral medicament of claim 1, comprising between 25 mg and 225 mg xanomeline and between 5 mg and 60 mg trospium chloride in a single dosage form used during the 24-hour period.